Analysis Shows Credo’s VitaPCR™ SARS-CoV-2 Related Assays Covers New Virus Strain
Credo Diagnostics Biomedical Pte. Ltd., the leader of point-of-care rapid molecular diagnostic, announced today it has completed internal analysis and confirmed that all its VitaPCR™ SARS-CoV-2 related assays – including the VitaPCR™ SARS-CoV-2 Assay, the VitaPCR™ SARS-CoV-2 Gen 2 Assay, and the Influenza A&B/SARS-CoV-2 Assay – can successfully detect the newly discovered variant strain of […]
